Vincerx is poised to deliver paradigm-shifting therapeutics to address the unmet medical needs of patients with cancer. We have a versatile toolbox of innovative linkers, payloads and bioconjugation chemistries to advance the next generation of small molecule and antibody–drug conjugates with the potential for making significant inroads into the fight against some of the more intractable forms of cancer.
Vincerx has an experienced management and scientific team to advance the company’s therapeutic platform of next generation antibody-drug conjugate (ADC) candidates from discovery to approval, including leveraging the synergies of licensing or strategic partnerships. The company’s goal is to rapidly identify candidate ADCs against promising targets or address challenges of clinical-stage antibodies whose development into ADCs has been limited by current payload and linker technologies. In addition,
our novel first-in-class small molecule drug conjugate (SMDC) has compelling preclinical efficacy across multiple cancer types and is advancing toward the clinic.
Our company’s modular platform offers many partnership opportunities to develop innovative next-generation ADCs and first-in-class small molecule drug conjugates.